TransMedics, Inc., the global leader in organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.
"TransMedics is revolutionizing the field of solid organ preservation for transplantation and is well positioned to become the worldwide market leader," said David Abrams, Managing Member of Abrams Capital. "We led this investment because we believe that TransMedics has the right combination of superior products, market strategy and leadership to transform the organ transplant market and improve the quality of life for people around the world," said Travis Rhodes, Managing Director at Abrams Capital. Both Mr. Abrams and Mr. Rhodes have joined TransMedics' Board of Directors.
"We are committed to capitalizing on this market opportunity and creating significant shareholder value," said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. "This financing enables us to complete our heart and lung FDA pivotal trials and expand our global commercial activities."
Revolutionizing ex- vivo perfusion of donor organs at leading transplant centers around the world, TransMedics' Organ Care System (OCS™) Heart device is recognized as a top medical innovation by Cleveland Clinic, CNN and Popular Science. Most recently, the OCS Lung device was featured in The Lancet, a prestigious medical journal, in an article detailing the superior clinical results in high-risk lung transplant recipients.